An article recently published on this topic in Dynamics, the Journal of the Canadian Association of Critical Care Nurses (entitled "ALERT: Mix-ups between conventional and lipid formulations of amphotericin B can be extremely dangerous.
Intravenous amphotericin is currently marketed in Canada as conventional (non-lipid) amphotericin B (Fungizone[R]) and as lipid formulations (AmBisome[R]--a liposomal formulation, and Abelcet[R]--a lipid complex formulation).
To show comparable blood levels to existing commercial versions of Amphotericin B, which are administered via IV infusion, is exciting to us as there is a clear commercial medical need for an oral antifungal with the strength and breadth of action of Amphotericin.
These observations suggest that alterations in sample turbidity related to liposomal amphotericin B rather than increased triglyceride values may have contributed to the false increases of phosphorus values.
Current treatment guidelines, which advocate amphotericin B as induction therapy, are based on a large randomised controlled trial (RCT) from the USA that compared initial therapy with amphotericin B (0.
Recent guidelines from the National Institute of Allergy and Infectious Diseases Mycoses Study Group and the Infectious Diseases Society of America suggest that life-threatening pulmonary or disseminated non-CNS disease, any CNS disease, and disease in the immunocompromised host be treated with amphotericin B to complete a total dose of 1.
A February 2010 Indian study published in The New England Journal of Medicine found that a single dose of AmBisome 10mg/kg is safe, effective and significantly less expensive than the 15 infusions of amphotericin B deoxycholate over the course of a 29-day hospitalization.